Avidity Biosciences INVESTORS | NEWS RELEASES ABOUT AVIDITY Our mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – AOCs. Our proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Our advancing and expanding pipeline includes multiple skeletal muscle programs. We are also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Learn More Investor Alerts YEAR All Years 2021 2020 2019 2018 2017 KEYWORDS GO NOV 9, 2021 Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported... NOV 4, 2021 Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™) Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced... Video 1 NOV 2, 2021 Avidity Biosciences to Participate in Upcoming Investor Conferences Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced... OCT 18, 2021 FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced... AUG 31, 2021 Avidity Biosciences to Participate in Upcoming Investor Conferences Avidity Biosciences, Inc. (NASDAQ: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced... Show 5 per page «12345678910» © 2021 Avidity Biosciences EXPLORE About Platform Pipeline Patients Investors Contact Careers CONTACT 10578 Science Center Dr. Suite 125 San Diego, CA 92121 info@aviditybio.com Tel: 858-401-7900 FOLLOW LEGAL Patents